Pancreatic cancer, one of the most aggressive and deadly forms of cancer, has long been a formidable challenge for patients and doctors alike. With a dismal 5-year survival rate of just 13% and recurrence rates as high as 84% after surgery, the need for innovative treatments has never been more urgent. Now, a groundbreaking study by a research team lead Dr. Nicholas H. Oberlies, University of North Carolina at Greensboro, has unveiled a revolutionary approach that could transform the landscape of pancreatic cancer treatment: drug-loaded surgical buttresses designed to prevent tumor recurrence after surgery. This cutting-edge technology offers new hope for patients, promising improved outcomes and reduced toxicity.

High recurrence rates limit treatment options for pancreatic cancer

Despite advancements in surgical techniques and chemotherapy, pancreatic cancer frequently recurs after treatment. Even when surgeons successfully remove the tumor, microscopic cancer cells can remain, leading to recurrence in most cases. Traditional therapies like systemic chemotherapy and radiation often fail due to drug resistance, severe side effects, and inadequate drug delivery to the tumor site. These challenges have driven researchers to develop more effective and safer strategies to eliminate residual cancer cells. Emerging targeted drug delivery systems, such as nanoparticle-based formulations and hydrogel drug carriers, have shown promise in increasing local drug concentration while minimizing systemic toxicity. However, these approaches still face challenges related to stability, controlled drug release, and clinical translation.

Drug-loaded biomaterial scaffolds or surgical buttresses: A promising drug delivery system for treating or preventing recurrence of cancers

Previous studies have explored drug-loaded biomaterial scaffolds or surgical buttresses to enhance localized chemotherapy and reduce cancer recurrence. In liposarcoma and chondrosarcoma mouse models, doxorubicin-loaded meshes nearly eliminated recurrence, with only one case observed. The targeted delivery of a gemcitabine HCl-loaded microdevice and a 3D-printed 5-fluorouracil patch has been shown to reduce tumor growth with minimal systemic toxicity in murine models. While these studies examined targeted drug delivery for pancreatic tumors, few have focused on resection models, underscoring the need for more research in this area.

Verticillin A-loaded surgical buttresses: Rationale for localized drug delivery in pancreatic cancer

Verticillin A, a fungal metabolite, is a potent histone methyltransferase inhibitor with strong anti-tumor properties. It regulates apoptosis, the cell cycle, and stress responses, and enhances the efficacy of immune checkpoint inhibitors by modulating PD-L1 expression. However, systemic administration of Verticillin A is limited by toxicity at doses above 3 mg/kg. To address this, the study proposes a localized delivery system using surgical buttresses, which are bioabsorbable materials applied during surgery to reinforce tissue and reduce the risk of tumor recurrence. By embedding Verticillin A into these buttresses, sustained drug release can be achieved at the tumor site, minimizing systemic exposure and toxicity.

How it works: Precision medicine at its best

  • The surgical buttress is designed to deliver verticillin A directly to the tumor site, maximizing its cancer-fighting potential while minimizing exposure to healthy tissues (Fig.1). Key features of this system include:
  • Controlled Release: Only 12% of the drug is released in the first 24 hours, with 60% released by day 21 and 80% by day 90. This extended release is crucial for targeting slow-growing cancer cells.
  • Bidirectional Delivery: The buttress releases the drug on both sides, ensuring it reaches the entire resection area without harming surrounding tissues.
  • Reduced Toxicity: Unlike systemic chemotherapy, which can cause severe side effects, the buttress-delivered drug showed no toxicity to the liver or kidneys in animal studies.

 

Fig. 1: Verticillin A-loaded surgical buttress for the prevention of pancreatic tumor recurrence

 

High-dose verticillin a significantly reduces tumor recurrence

The verticillin A-loaded surgical buttress has demonstrated remarkable efficacy and safety in preventing tumor recurrence. In a mouse model of pancreatic cancer, the buttress significantly reduced recurrence, with a high dose (800 μg) achieving an 80% reduction, while a low dose (100 μg) reduced recurrence by 40%. Both doses outperformed gemcitabine, a standard chemotherapy drug, which resulted in a 100% recurrence rate.
In terms of safety, systemic administration of verticillin A at high doses caused severe liver toxicity, whereas the buttress-delivered formulation was well tolerated at doses up to 40 mg/kg, 25 times higher than the systemic maximum tolerated dose. Additionally, the loaded buttresses maintained cytotoxic effects for 7–10 weeks in laboratory studies, making them particularly effective for targeting slow-growing cancer cells.

Future applications: Beyond pancreatic cancer

According to the article, further studies are ongoing to advance the in vivo testing of verticillin A across various tumor models. The success of this study paves the way for numerous possibilities in cancer treatment. One potential application is expanding the buttress technology to other cancers where surgery is a primary treatment, such as lung, ovarian, and colorectal cancers. Additionally, the buttress could be utilized for combination therapies, allowing multiple drugs to be loaded or paired with immunotherapy to enhance its effectiveness. Furthermore, this technology holds promise for personalized medicine, as the drug-loading capacity and release kinetics can be tailored to individual patients, offering a more customized and targeted approach to cancer treatment.

Conclusion

The verticillin A-loaded surgical buttress represents a significant advancement in cancer treatment by providing targeted, sustained chemotherapy directly to the tumor site. This innovative approach overcomes the limitations of current therapies and offers new hope for patients. One of its key advantages is direct tumor targeting, which maximizes drug efficacy at the resection site while minimizing exposure to healthy tissues. Additionally, the sustained drug release mechanism prevents rapid drug clearance, reducing the need for multiple chemotherapy cycles. Moreover, this method significantly reduces side effects, helping to avoid common chemotherapy-induced toxicities such as liver damage, nausea, and immune suppression.
With further development, this pioneering technology could revolutionize pancreatic cancer treatment and provide a safer, more effective strategy for preventing tumor recurrence in multiple types of solid tumors.

References

1. Verticillin A-loaded surgical buttresses prevent local pancreatic cancer recurrence in a murine model.
2. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression.
3. Bioinspired adhesive microneedle patch with gemcitabine encapsulation for pancreatic cancer treatment.
4. Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrence

Disclaimer: This information is intended solely for research purposes and does not serve as medical advice.

Our Recent Publication/Meeting Presentation

American Society of Hematology (ASH) Annual Meeting 2024.

Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories

Our Recent Blogs/Articles